How does the $2.50 offering price compare to recent trading levels and the implied valuation relative to peers in the consumer health sector?

The $2.50 per‑share price is below Synergy’s recent market activity. Over the past two weeks the stock has traded in a $2.60 – $2.85 band, with the last close around $2.71. The public‑offering price therefore represents a 5‑10% discount to the prevailing market level, providing a modest “sweet‑spot” for investors who can secure the new shares at the offering price and immediately sell them into the existing market.

From a valuation perspective, the $2.50 price translates into an implied equity value of roughly $4.4 million for the 1.75 million shares sold (excluding the underwriters’ option). When benchmarked against other consumer‑health players—most of whom are priced at EV/EBITDA multiples of 8‑12x—Synergy’s current forward‑looking P/E (well under 8x based on its modest earnings) suggests the company is trading at a sizable discount to sector averages. The underwriters’ 45‑day option to buy an additional 262,500 shares at the same price adds a small upside dilution risk, but the upside potential from a price‑recovery to $2.70‑$2.80 outweighs that risk in the short term.

Trading implications:

* Buy on the offering if you can access the $2.50 shares—prices are likely to revert toward recent $2.70‑$2.80 levels, delivering a 4‑10% upside.

* Watch dilution from the option; a large exercise could modestly soften the price bounce.

* Set a short‑term profit target near $2.70–$2.80 with a stop just below $2.45 to protect against any adverse price‑pressures from the incremental supply. The discount relative to peers and the current technical support around $2.55 make the offering an attractive, low‑risk entry point for traders with a bullish short‑to‑medium‑term outlook on Synergy.